Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of ...

Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on Biotech Distilled’s Substack.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mornings like we had on Wednesday are exactly why I get up and ...

AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus ...

American Homes 4 Rent (AMH) — BMO Capital Markets raised its price target to $39.00 from $36.00 and maintained a Market Perform rating. AMETEK (AME) — Citigroup initiated coverage of AMETEK with a ...

Fresh off a deal with Travere Therapeutics Inc. for civorebrutinib worth more than $1.14 billion, Everest Medicines Ltd. went on a shopping spree, striking three deals in six days to expand its ...

Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to ...